Enliven Therapeutics, Inc.
General ticker "ELVN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.6B (TTM average)
Enliven Therapeutics, Inc. follows the US Stock Market performance with the rate: 46.2%.
Estimated limits based on current volatility of 2.2%: low 52.68$, high 55.06$
Factors to consider:
- Earnings expected soon, date: 2026-08-12 bmo
- Total employees count: 60 (-3.2%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: No approved products, Net losses, ELVN 001 failure, Regulatory and compliance, Manufacturing risks
- Current price 128.1% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.29$, 24.03$]
- 2026-12-31 to 2027-12-31 estimated range: [8.71$, 20.77$]
Financial Metrics affecting the ELVN estimates:
- Negative: with PPE of -8.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.59 <= 0.30
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Positive: Shareholder equity ratio, % of 96.52 > 63.79
Short-term ELVN quotes
Long-term ELVN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $83.53MM | $104.55MM | $119.66MM |
| Operating Income | $-83.53MM | $-104.55MM | $-119.66MM |
| Non-Operating Income | $11.95MM | $15.76MM | $15.96MM |
| R&D Expense | $64.57MM | $80.78MM | $85.86MM |
| Income(Loss) | $-71.58MM | $-88.79MM | $-103.69MM |
| Taxes | $0.00MM | $0.23MM | $0.00MM |
| Net Income(Loss)* | $-71.58MM | $-89.02MM | $-103.69MM |
| Stockholders Equity | $245.91MM | $309.85MM | $459.60MM |
| Assets | $271.87MM | $325.76MM | $476.17MM |
| Operating Cash Flow | $-61.27MM | $-73.19MM | $-70.30MM |
| Capital expenditure | $0.15MM | $0.04MM | $0.16MM |
| Investing Cash Flow | $-148.41MM | $-36.00MM | $-173.84MM |
| Financing Cash Flow | $234.29MM | $133.16MM | $218.87MM |
| Earnings Per Share** | $-2.01 | $-1.89 | $-1.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.